Novo Nordisk pairs with OpenAI

Novo Nordisk said Tuesday it is bringing OpenAI’s artificial intelligence tools into drug research, manufacturing and commercial work across the company. (finance.yahoo.com) The Danish drugmaker said the partnership will use OpenAI’s models to analyze large biological datasets, search for new molecules and shorten the path from early research to patient use. Novo Nordisk said the rollout starts with a pilot across research and development, manufacturing and commercial teams, with broader integration planned by the end of 2026. (finance.yahoo.com) (pharmaceutical-technology.com) Novo Nordisk said the agreement includes workforce training, data-governance controls and human oversight for how the tools are used. Chief executive Mike Doustdar said the company sees “therapies still waiting to be discovered” for people with obesity and diabetes. (finance.yahoo.com) (cnbc.com) Drug discovery starts with a basic problem: researchers must sift through huge amounts of genetic, chemical and clinical data to find a molecule worth testing in animals and humans. Artificial intelligence systems are being pitched as faster pattern-finders that can rank targets, spot molecule candidates and help scientists decide which experiments to run first. (cnbc.com) (euronews.com) Novo Nordisk made the OpenAI move on the same day Britain’s Medicines and Healthcare products Regulatory Agency approved a single-dose Wegovy pen that delivers 7.2 milligrams of semaglutide once a week. The agency said on April 14 that the new pen is for adults with obesity with a body mass index of 30 kilograms per square meter or higher. (gov.uk) (pharmiweb.com) That device approval followed an earlier British decision on January 6, 2026, to allow Wegovy dosing up to 7.2 milligrams per week for obesity. The April 14 action cleared a pen that gives that full maintenance dose in one injection instead of three 2.4 milligram injections taken together. (gov.uk 1) (gov.uk 2) Novo Nordisk also expanded the higher-dose strategy in the United States last week. Reuters reported on April 7 that the company had made a 7.2 milligram version, branded Wegovy HD, available in the United States after a March approval. (money.usnews.com) The backdrop is a tougher obesity-drug market. Novo Nordisk, whose biggest brands include Wegovy and Ozempic, is under pressure to find new medicines, improve supply and defend share as Eli Lilly pushes deeper into obesity treatment. (techxplore.com) (nationaltoday.com) Taken together, Tuesday’s announcements show Novo Nordisk trying to speed both ends of the same business: finding the next treatment in software and getting the current one into a simpler pen. (finance.yahoo.com) (gov.uk)